Navigation Links
PRA Executive to Present at Outsourcing Conference
Date:7/20/2011

RALEIGH, N.C., July 20, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that the head of our Scientific and Medical Affairs group, Kent Thoelke, will discuss critical issues in medical informatics and feasibility at the 3rd Annual Effective Business Development Outsourcing Relationships Conference being held 19-21 July 2011 in Philadelphia.

On Thursday, 21 July, Mr. Thoelke will co-host the session, "Rising to the Challenge of Global Feasibility through Medical Informatics." The presentation's highlights include using medical informatics as a data-driven approach to plan clinical trials, practical considerations for particular patient populations, and how to develop multi-country scenarios to meet enrollment milestones.

In his role as Senior Vice President at PRA, Mr. Thoelke directs our medical informatics and therapeutic expertise programs, providing scientific and strategic oversight of product development to empower project teams as they execute clinical trials on behalf of our clients. He has over 19 years of wide-ranging experience in global drug development and device industry. Having visited over 40 countries, he is familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world.

PRA's Medical Informatics group, which serves as a key component of our Scientific and Medical Affairs division, leads the industry in advancing evidence-based approaches for protocol validation, study feasibility and patient access.  To enhance global accrual rates for clinical trials, PRA has focused on mining public and private databases to create a proprietary methodology for patient and site access.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
2. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
3. Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc.
4. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
5. Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director
6. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
7. Ed Weimer Joins Delta Point, Inc. as Executive Account Director
8. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
9. The Clearity Foundation Hires Hillary Theakston as Executive Director
10. Savient Pharmaceuticals Announces Executive Appointments
11. IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO┬«). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
Breaking Biology News(10 mins):